News Search Results
Oct 21, 2025, 08:00 ET Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related
More news about: Citius Pharmaceuticals, Inc.
Oct 20, 2025, 19:39 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed
More news about: BioVaxys Technology Corp.
Oct 20, 2025, 09:00 ET RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
per year), a major risk factor for peptic ulcer disease (90% of cases)9 and gastric mucosa-associated lymphoid tissue (MALT) lymphoma10. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients
More news about: RedHill Biopharma Ltd.
Oct 20, 2025, 08:37 ET Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
About Cutaneous T-cell Lymphoma Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that
More news about: Citius Oncology, Inc.
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin
More news about: AbbVie
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
Annual Meeting, December 6-9, 2025– Poster presentation of the first-in-human Phase 1 study of HCB101 in relapsed/refractory non-Hodgkin lymphoma ESMO Immuno-Oncology Congress (ESMO-IO), December 10-12, 2025– One abstract integrating the HCB101 monotherapy
More news about: HanchorBio Inc.
Oct 17, 2025, 17:00 ET Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related
More news about: Citius Pharmaceuticals, Inc.
Oct 17, 2025, 06:22 ET Weekly Recap: 14 Health Press Releases You Need to See
More People Affected by Blood Cancer The out-of-home campaign introduces The Leukemia & Lymphoma Society's new name, Blood Cancer United, to engage more communities and increase awareness of blood cancer.
More news about: PR Newswire
Oct 17, 2025, 01:32 ET FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients
More news about: Celltrion USA
Oct 16, 2025, 17:31 ET Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight
Indolent Lymphoma? Indolent lymphoma is a slow-developing form of non-Hodgkin lymphoma that mainly involves B cells and can take several years to advance. Key subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma (SLL)/chronic
More news about: DelveInsight Business Research, LLP
Oct 16, 2025, 08:47 ET Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
About Cutaneous T-cell Lymphoma Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in
More news about: Citius Oncology, Inc.
Oct 15, 2025, 10:40 ET Commercial Distributed Energy Generation Market Size Worth USD 367.8 Billion by 2033, Growing at 11.0% CAGR from 2026-2033 : - Market Research Intellect
Global Checkpoint Inhibitors For Treating Cancer Market Size By Application (Lung Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma, Head and Neck Cancers), By Product (PD-1 Inhibitors (Programmed Cell Death Protein 1), PD-L1 Inhibitors (Programmed Death-Ligand 1), CTLA-4 Inhibitors
More news about: Market Research Intellect
Oct 15, 2025, 10:00 ET The Leukemia & Lymphoma Society, now Blood Cancer United, collaborates with The US Oncology Network to advance care in community cancer centers
WASHINGTON, Oct. 15, 2025 /PRNewswire/ -- The Leukemia & Lymphoma Society, now Blood Cancer United®, and
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Oct 14, 2025, 08:30 ET India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care
treatment protocols. It features India's first community-based Cancer Tissue Biobank, enabling advanced genomic research in paediatric leukaemia and lymphoma. With a total sum of INR 56 Crore committed towards this initiative, HMIF has also established a dedicated INR 3 Crore Cancer
More news about: IIT Madras
Oct 14, 2025, 08:30 ET India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care
treatment protocols. It features India's first community-based Cancer Tissue Biobank, enabling advanced genomic research in paediatric leukaemia and lymphoma. With a total sum of INR 56 Crore committed towards this initiative, HMIF has also established a dedicated INR 3 Crore Cancer
More news about: IIT Madras
Oct 14, 2025, 08:05 ET Clear Channel Outdoor and Blood Cancer United Team Up on Billboard Campaign to Reach More People Affected by Blood Cancer
Out-of-Home Campaign Introduces The Leukemia & Lymphoma Society's New Name, Blood Cancer United, to Engage More Communities and Increase Awareness of Blood Cancer
More news about: Clear Channel Outdoor
Oct 14, 2025, 08:00 ET BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
includes maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed
More news about: BioVaxys Technology Corp.
Oct 14, 2025, 07:30 ET Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Director of Cutaneous Lymphoma at the Inova Schar Cancer Institute, heading a high-volume cutaneous lymphoma subspecialty clinic where she treats over 1,000 lymphoma patients. She is an experienced clinical researcher, serving as principal investigator on numerous Phase 1-3 cutaneous lymphoma trials, and she
More news about: Soligenix
Oct 13, 2025, 10:57 ET U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer. Increased risk of major cardiovascular
More news about: AbbVie
Oct 13, 2025, 07:30 ET ADC Therapeutics Announces $60 Million Private Placement
with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily
More news about: ADC Therapeutics SA
Oct 13, 2025, 05:30 ET Lupin kündigt Präsentation von Phase-1-Daten zu LNP3693 (STING-Agonist) auf dem ESMO-Kongress 2025 an
dem Titel „A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma" (Phase-1-Dosis-Eskalationsstudie von LNP3693 (STING-Agonist) bei Patienten mit fortgeschrittenen oder metastasierten soliden Tumoren und Lymphomen)
More news about: Lupin Limited
Oct 13, 2025, 05:30 ET Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
presentation, titled 'A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma,' will be featured in the Investigational Immunotherapy session (Presentation Number 1553P). It can be viewed on October 19, 2025,
More news about: Lupin Limited
Oct 13, 2025, 05:30 ET Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
presentation, titled 'A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma,' will be featured in the Investigational Immunotherapy session (Presentation Number 1553P). It can be viewed on October 19, 2025,
More news about: Lupin Limited
Oct 13, 2025, 05:30 ET Lupin annonce la présentation de données de phase I sur le LNP3693 (agoniste de STING) au congrès ESMO 2025
intitulée « A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma » (Étude d'augmentation de dose de phase I de LNP3693 (agoniste de STING) chez les patients atteints de tumeurs solides au stade avancé ou métastatiques
More news about: Lupin Limited
Oct 09, 2025, 09:30 ET My Fairy Godfathers Foundation Celebrates 'Oscar Night' Raising Nearly $200K at Annual Charity Ball in Tampa, FL
human spirit was the heartfelt speech from wig and beauty experience recipient, Arianna Murrow of New York. She was diagnosed with stage 2 Hodgkin's Lymphoma as a high school senior and met with an avalanche of emotions. "Cancer wouldn't take my hope. I submitted college applications from my hospital bed
More news about: My Fairy Godfathers